Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flux Power Holdings Inc (FLUX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Flux Power Holdings IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Flux Power Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Flux Power Holdings Inc trades at $0.7 (market cap $15.37M), while Vertex Pharmaceuticals Incorporated trades at $483.06 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7878.3× Flux Power Holdings Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.

FLUXVRTX
Market Cap
$15.37M$121.09B
Sector
UtilitiesHealth
52-Week High
$6.66$529.59
52-Week Low
$0.71$366.54
Enterprise Value
$21.53M$115.83B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flux Power Holdings Inc

No Aura AI signal available yet.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.

The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Flux Power Holdings Inc

Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.

Read more on FLUX

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX